7:30 am Registration & Light Breakfast

8:25 am Chair’s Opening Remarks

Examining Next-Gen Clinical Models that Better Recapitulate Chronic & Progressive Fibrotic Diseases to Build Translational Confidence in Early Development Candidates

8:30 am Leveraging Human Tissue Models for Discovery & Development: A Novel Approach to Preclinical Development


  • Examining human-centric discovery with deep phenotyping and RNA chemistry
  • Uncovering ex-vivo human-organ perfusion models for the identification, characterization and validation of late-stage liver disease targets

9:00 am Moving Beyond Acute Models Which Lack the Recapitulation of Human Fibrosis Necessary for Translational Confidence, to Chronis Models of Fibrosis


  • Overcoming the lack of preclinical models which do not recapitulate the slow and progressive nature of human fibrosis
  • Critically evaluating the predictive power of novel models including patient-derived organoids, 3D tissue engineering platforms, and genetically engineered animal models

9:30 am Developing Advanced Preclinical Models that Better Recapitulate Disease & Patient Heterogeneity & Pathophysiology

  • Joseph Wu Director of Stanford Cardiovascular Institute, Professor of Medicine & Radiology, Stanford University


  • Explore cutting-edge preclinical models that more accurately mimic the complexity and variability of human fibrotic diseases, capturing the nuances of patient heterogeneity and disease pathophysiology
  • Uncover how advanced preclinical systems improve the predictive power for clinical outcomes, bridging the gap between early research and human trials with greater fidelity

10:00 am Speed Networking


This informal session provides the perfect opportunity to connect with the industry frontrunners and key opinion leaders focusing on fibrosis across the Lung, Liver, Kidney, Cardiac, Gastrointestinal and Scleroderma Landscapes. Establish meaningful connections to build upon for the rest of the conference and gain exclusive first-hand insights into the latest research and developments driving progression across the cross fibrosis disease field.

10:45 am Morning Break

Examining Non-Invasive Measures of Disease Progression Tracking & Clinical Efficacy with Novel Biomarkers & the Latest Technological Advances in Imaging Technologies

11:00 am Round Table Discussion: Leveraging Non-Invasive Biomarkers for Disease Progression Tracking and Clinical Efficacy


This interactive session gives you the opportunity to be part of the discussion, get ready to share ideas and learn from your peers. Amongst your table’s talking points to consider include:

The Role of Advanced Imaging Technologies in Biomarker Development

What are the limitations and challenges of
integrating these imaging technologies into clinical practice?
Share examples where advanced imaging
has significantly impacted fibrosis research

Standardization and Validation of Non-Invasive Biomarkers

What are the critical steps in the
standardization and validation process of
non-invasive biomarkers for fibrosis?
How can we ensure reproducibility and
consistency across different laboratories
and clinical settings?

Translational Applications and Clinical Implementation

How can non-invasive biomarkers be
effectively translated from research to
clinical applications?
What are the potential impacts of these
biomarkers on patient care and treatment
outcomes in fibrosis?

11:30 am Leveraging Non-Invasive Imaging & Mass Spectrometry Technologies to Quantify Fibrosis

  • Tim McKinsey Director, Consortium for Fibrosis Research & Translation, University of Colorado Denver


  • Explore how prequalified and validated antibodies are used to visualize ECM proteins and fibrillar collagen through immunoblotting and immunohistochemistry
  • Discover the use of second harmonic generation (SHG) microscopy and fluorescence lifetime imaging microscopy (FLIM) for quantifying fibrotic lesions in living rodents
  • Learn about the application of LC-MS/MS protocols to quantify distinct forms of collagen, crucial for understanding the mechanisms of fibrosis

Mitigating the Heterogenous & Complex Nature of Fibrotic Diseases with Innovative Therapeutic Strategies

12:00 pm Examining the Molecular Profile of Responders & Non-Responders to Segment Heterogenous Disease Populations

  • Francesco Del Galdo Professor of Experimental Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine


  • Examining the molecular and cellular changes in patients who respond to therapy and secondary changes that occur beyond the immediate impact of the drug to reveal critical insights into disease mechanisms and therapeutic efficacy
  • Exploring retrospective analysis to uncover predictive biomarkers and how these can enhance confidence in therapeutic decisions and patient stratification improving patient outcomes
  • Analysis of molecular changes in non-responders compared to responders to uncover insights into potential treatment gaps and the need for additional or alternative therapies

12:30 pm Lunch Break

1:30 pm Leveraging Patient Data & Clinical Endpoints for Reverse Translation: Uncovering Efficacious Targets in Fibrotic Diseases

  • Alex Barron Principal Scientist II, Fibrosis Group, Novartis


  • Examine how large-scale patient data sets can inform early-stage drug discovery and how to leverage these patient data sets to identify potential causative targets
  • Highlighting the connection between functional endpoints and anti-fibrotic effects to understand which functional clinical endpoints are good surrogates for antifibrotic efficacy and targets with a higher probability of being associated with worse disease severity

2:00 pm Integrating Therapeutic Platform with Biomarkers & Genetic Analysis for Novel Targets that Mitigate the Heterogenous Nature of Fibrotic Diseases


  • Exploring the unique dual action of AM1476’s and its potential addresses the heterogeneous nature of systemic sclerosis and other fibrotic indications
  • Investigating AnaMar’s integration of their therapeutic platform with biomarkers and genetic analysis to enhance the precision and efficacy of AM1476
  • Using novel genetic marker approaches using a gene signature to identify responders to treatment

3:00 pm Poster Session


Immerse yourself in an engaging session in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own research and developments in the Inflammasome therapeutics space. Don’t miss out on the chance to connect, learn, and present. Get ready to be impressed!

Exploring Target Product Profile & Expansion Strategies to Shape Future Asset Prioritization

4:00 pm Shaping the Future of Antifibrotic Therapeutics with Exploration of Expansion Opportunities & Key Considerations

  • Jack Castle Head of Corporate Development, Ochre Bio
  • Andy Whittle Director, Strategic Partnering, Cardiometabolism & Retinal Health, Boehringer Ingelheim
  • David Lagares Chief Executive Officer & Founder, Zenon Biotech


This session will explore and evaluate emerging trends, identify innovative approaches to differentiate products and strategic insights on how to advance antifibrotic drug development and patient care across a broad spectrum of diseases. Examine the driving factors behind progress and how best to capitalize on these to explore your future expansion strategies.

4:30 pm Examining Target Product Profile: From Signalling Cascades to Cell Types & Immunomodulatory Proteins – What is the Best Target & Most Effective Modality


  • Discuss the most promising signalling cascades, cell types, and immunomodulatory proteins that can be targeted to effectively combat fibrosis
  • Analyse different therapeutic modalities, including small molecules, biologics, and gene therapies, to identify the most effective and precise approach to targeting fibrosis with as few side effects as possible

5:00 pm Panel & Audience Discussion: Collaborative Strategies for Advancing Antifibrotic Drug Development Across Diverse Disease Indications

  • Jack Castle Head of Corporate Development, Ochre Bio
  • Joseph Wu Director of Stanford Cardiovascular Institute, Professor of Medicine & Radiology, Stanford University
  • Francesco Del Galdo Professor of Experimental Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine
  • Geoffrey Teixeira Senior Vice President, Head of Fibrosis, Alentis Therapeutics
  • Anil Karihaloo Senior Principal Scientist - Research, Novo Nordisk
  • Scott Turner Chief Scientific Officer, Arda Therapeutics
  • Katie McCauley Head of Fibrosis Research, Novartis


This panel discussion gathers experts from across the various disease indications to discuss what is needed to collectively advance antifibrotic drug development across the broad spectrum of diseases.

Expect coverage of:

  • With an increase recognition of the complexity and heterogeneity of fibrotic diseases, will combination therapies be necessary to secure clinical efficacy above the current standards of care?
  • What is the true bottleneck halting progression of antifibrotic therapeutics through the clinical and to patients?
  • Do we need to focus on detecting higher risk patients for earlier diagnosis and earlier intervention to prevent late-stage fibrosis?
  • Where should we be directing future research efforts?

5:30 pm Chairs Closing Remarks

End of Day One